Anti-HIV drugs for cancer therapeutics: back to the future?

[1]  W. Hohenberger,et al.  Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[3]  K. Samaras.  Metabolic consequences and therapeutic options in highly active antiretroviral therapy in human immunodeficiency virus-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[4]  Hiroaki Mitsuya,et al.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV. , 2007, Bioorganic & medicinal chemistry.

[5]  Thomas C. Chen,et al.  HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. , 2007, Cancer research.

[6]  Robert H. Shoemaker,et al.  Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo , 2007, Clinical Cancer Research.

[7]  N. Urbano,et al.  Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine. , 2007, Cancer biotherapy & radiopharmaceuticals.

[8]  S. Hahn,et al.  Phosphatase and tensin homologue deficiency in glioblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir. , 2007, Cancer research.

[9]  J. Gschwend,et al.  389 NEW HIV-DRUG INHIBITS IN VITRO BLADDER CANCER MIGRATION AND INVASION , 2007 .

[10]  K. Flaherty,et al.  HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest. , 2007, Cancer research.

[11]  M. Luppi,et al.  A non-chemotherapy treatment of a primary effusion lymphoma: durable remission after intracavitary cidofovir in HIV negative PEL refractory to chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Koeffler,et al.  NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines , 2006, British Journal of Cancer.

[13]  S. Hahn,et al.  Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. , 2006, Cancer research.

[14]  W. Chow,et al.  Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by upregulating sterol regulatory element binding protein-1 , 2006, Anti-cancer drugs.

[15]  Arun K. Ghosh,et al.  Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. , 2006, Journal of medicinal chemistry.

[16]  H. Koeffler,et al.  HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. , 2006, Leukemia research.

[17]  E. Palescandolo,et al.  Evaluation of Antitumoral Properties of the Protease Inhibitor Indinavir in a Murine Model of Hepatocarcinoma , 2006, Clinical Cancer Research.

[18]  Christie M. Orschell,et al.  Effects of HIV Protease Inhibitor Ritonavir on Akt-Regulated Cell Proliferation in Breast Cancer , 2006, Clinical Cancer Research.

[19]  Mamoru Ito,et al.  leukemia cells by an HIV protease inhibitor, ritonavir , 2005 .

[20]  H. Kitchener,et al.  Specific HIV Protease Inhibitors Inhibit the Ability of Hpv16 E6 to Degrade P53 and Selectively Kill E6-Dependent Cervical Carcinoma Cells In Vitro , 2005, Antiviral therapy.

[21]  A. Baldi,et al.  Effects of indinavir in a preliminary phase I study on dogs with stage III slenic hemangiosarcoma. , 2006, In vivo.

[22]  A. Doria,et al.  The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. , 2006, Haematologica.

[23]  C. Basbaum,et al.  New HIV-drug inhibits in vitro bladder cancer migration and invasion. , 2005, European urology.

[24]  P. Opolon,et al.  Combined radiation sensitizing and anti-angiogenic effects of ionizing radiation and the protease inhibitor ritonavir in a head and neck carcinoma model. , 2005, Anticancer research.

[25]  F. Giorgino,et al.  Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. , 2005, The Journal of clinical endocrinology and metabolism.

[26]  Rosemarie Mick,et al.  HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. , 2005, Cancer research.

[27]  Y. Ohtsuki,et al.  HIV‐1 protease inhibitor induces growth arrest and apoptosis of human prostate cancer LNCaP cells in vitro and in vivo in conjunction with blockade of androgen receptor STAT3 and AKT signaling , 2005, Cancer science.

[28]  P. Sinibaldi-Vallebona,et al.  Inhibition of endogenous reverse transcriptase antagonizes human tumor growth , 2005, Oncogene.

[29]  W. Harrington,et al.  Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha. , 2005, Leukemia research.

[30]  Elke S. Bergmann-Leitner,et al.  Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner] , 2005 .

[31]  L. Cavanna,et al.  Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir , 2005, Leukemia.

[32]  P. Monini,et al.  Antitumour effects of antiretroviral therapy , 2004, Nature Reviews Cancer.

[33]  Y. Ohtsuki,et al.  HIV-1 Protease Inhibitor, Ritonavir , 2004, Cancer Research.

[34]  M. Staudt,et al.  The Tumor Microenvironment Controls Primary Effusion Lymphoma Growth in Vivo , 2004, Cancer Research.

[35]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[36]  P. André,et al.  Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. , 2004, Molecular cancer therapeutics.

[37]  R. Zeldin,et al.  Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. , 2003, The Journal of antimicrobial chemotherapy.

[38]  Y. Ohtsuki,et al.  HIV-1 Protease Inhibitor , Ritonavir : A Potent Inhibitor of CYP 3 A 4 , Enhanced the Anticancer Effects of Docetaxel in Androgen-Independent Prostate Cancer Cells In vitro and In vivo , 2004 .

[39]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Monini,et al.  Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. , 2003, The Lancet. Oncology.

[41]  A. Otaka,et al.  T140 analogs as CXCR4 antagonists identified as anti‐metastatic agents in the treatment of breast cancer , 2003, FEBS letters.

[42]  C. Wollheim,et al.  The Transcription Factor SREBP-1c Is Instrumental in the Development of β-Cell Dysfunction* , 2003, The Journal of Biological Chemistry.

[43]  J. Niland,et al.  Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies , 2003, Cancer Chemotherapy and Pharmacology.

[44]  G. Barber,et al.  Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. , 2003, Blood.

[45]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[46]  R. Kaufman.  Orchestrating the unfolded protein response in health and disease. , 2002, The Journal of clinical investigation.

[47]  Frank Pajonk,et al.  The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. , 2002, Cancer research.

[48]  R. D’Aquila,et al.  The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1) , 2002, AIDS.

[49]  M. Reitz,et al.  Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. , 2002, Blood.

[50]  W. Rozenbaum,et al.  Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance , 2002, The Lancet.

[51]  M. Falchi,et al.  HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma , 2002, Nature Medicine.

[52]  C. Fichtenbaum,et al.  HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the Nucleus* , 2001, The Journal of Biological Chemistry.

[53]  E. De Clercq,et al.  Potent inhibition of hemangiosarcoma development in mice by cidofovir , 2001, International journal of cancer.

[54]  Joseph L Goldstein,et al.  Regulated Intramembrane Proteolysis A Control Mechanism Conserved from Bacteria to Humans , 2000, Cell.

[55]  V. Beral,et al.  Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. , 2000 .

[56]  R. Coutinho,et al.  Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults , 2000 .

[57]  L. Boise,et al.  Azidothymidine and Interferon-α Induce Apoptosis in Herpesvirus-associated Lymphomas , 1999 .

[58]  B. Gazzard,et al.  Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. , 1999, AIDS.

[59]  A. Telenti,et al.  Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study , 1999, BMJ.

[60]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[61]  A. Palestine,et al.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. , 1999, The New England journal of medicine.

[62]  R. Gallo.  The Enigmas of Kaposi's Sarcoma , 1998, Science.

[63]  R M Zinkernagel,et al.  An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Hammer,et al.  Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. , 1998, Genes & development.

[65]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[66]  C. Pellet,et al.  Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV‐related Kaposi's sarcoma , 1998, AIDS.

[67]  C. Flexner.  HIV-protease inhibitors. , 1998, The New England journal of medicine.

[68]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[69]  A. Luster,et al.  Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.

[70]  E. De Clercq,et al.  The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. , 1998, Cancer research.

[71]  E. Horvath,et al.  In vitro antiviral drug sensitivity of the Kaposi's sarcoma‐associated herpesvirus , 1997, AIDS.

[72]  J. Goldstein,et al.  The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.

[73]  D. Ganem,et al.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. , 1997, The Journal of clinical investigation.

[74]  F. Gherlinzoni,et al.  3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas. , 1997, Blood.

[75]  Paul E. Kennedy,et al.  HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor , 1996, Science.

[76]  R. Danesi,et al.  Intravenous azidothymidine with fluorouracil and leucovorin: a phase I-II study in previously untreated metastatic colorectal cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  M. Dudley,et al.  High‐dose intravenous zidovudine with 5‐fluorouracil and leucovorin. A phase I trial , 1992, Cancer.

[78]  P. Tosi,et al.  Azidothymidine-induced cytotoxicity and incorporation into DNA in the human colon tumor cell line HCT-8 is enhanced by methotrexate in vitro and in vivo. , 1992, Cancer research.

[79]  J. Clark,et al.  High-Dose Intravenous Zidovudine with 5-Fluorouracil and Leucovorin , 1992 .

[80]  T. Szekeres,et al.  AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells. , 1991, Cancer communications.

[81]  A. Falcone,et al.  5-Fluorouracil enhances azidothymidine cytotoxicity: in vitro, in vivo, and biochemical studies. , 1990, Cancer Research.

[82]  P. Reiss,et al.  Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma. , 1989, AIDS.

[83]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[84]  M. Kashani-Sabet,et al.  Overexpression of DNA replication and repair enzymes in cisplatin-resistant human colon carcinoma HCT8 cells and circumvention by azidothymidine. , 1989, Cancer communications.

[85]  E. Gelmann,et al.  ADMINISTRATION OF 3'-AZIDO-3'-DEOXYTHYMIDINE, AN INHIBITOR OF HTLV-III/LAV REPLICATION, TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX , 1986, The Lancet.

[86]  D W Barry,et al.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[87]  James L. Gilbert,et al.  Rebuilding Big Pharma ’ s Business Model , 2022 .